Cargando…

Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan

IMPORTANCE: A surrogate end point (SEP) is an end point used in clinical trials as an alternative for measuring the true clinical benefit. The use of SEPs in trials shortens their duration. OBJECTIVES: To investigate the use of SEPs in clinical trials to support the approval of anticancer drugs and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maeda, Hideki, Shingai, Riko, Takeda, Kentaro, Hara, Asuka, Murai, Yuna, Ofuchi, Momoka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148198/ https://www.ncbi.nlm.nih.gov/pubmed/37115550 http://dx.doi.org/10.1001/jamanetworkopen.2023.8875

Ejemplares similares

Japan’s Special Approval for Emergency System During the COVID‐19 Pandemic
por: Maeda, Hideki
Publicado: (2021)

Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer
por: Maeda, Hideki, et al.
Publicado: (2021)

Comparing cancer drug approval systems in the United States and Japan
por: Kaneda, Yudai, et al.
Publicado: (2023)

Regulatory Approval With Real-World Data From Regulatory Science Perspective in Japan
por: Maeda, Hideki, et al.
Publicado: (2022)

Oncology approvals in 2020: a year of firsts in the midst of a pandemic
por: Amiri-Kordestani, Laleh, et al.
Publicado: (2021)

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
por: Chen, Emerson Y., et al.
Publicado: (2020)

Risk Factors for Epistaxis in Thoroughbred Flat Races in Japan (2001–2020)
por: Sugiyama, Fumi, et al.
Publicado: (2023)

Gridded Datasets for Japan: Total, Male, and Female Populations from 2001–2020
por: Li, Chao, et al.
Publicado: (2023)

Assessment of Drugs Approved by Public Knowledge‐Based Applications (Kouchi‐shinsei) During the Last Two Decades in Japan
por: Maeda, Hideki, et al.
Publicado: (2021)

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
por: Gyawali, Bishal, et al.
Publicado: (2020)

Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020
por: Haslam, Alyson, et al.
Publicado: (2021)

Research trends and areas of focus on cryoablation and oncology: A bibliometric analysis from 2001 to 2020
por: Liu, Hang, et al.
Publicado: (2022)

Cyclic peptide drugs approved in the last two decades (2001–2021)
por: Zhang, Huiya, et al.
Publicado: (2021)

Postmarketing all-case surveillance trends and contribution to safety measures of drugs approved in Japan: a cross-sectional survey in 1999–2019
por: Nakao, Minami, et al.
Publicado: (2022)

Kidney biopsy guidebook 2020 in Japan
por: Ubara, Yoshifumi, et al.
Publicado: (2021)

For approval preliminary draft budget of the organization for the forty-seventh financial year 2001
Publicado: (2000)

Use of surrogate outcomes in US FDA drug approvals, 2003–2012: a survey
por: Yu, Tsung, et al.
Publicado: (2015)

Repurposing Clinically Approved Drugs for the Treatment of Bacillus cereus, a Surrogate for Bacillus anthracis
por: Amakawa, Masami, et al.
Publicado: (2020)

Regulatory-approved deep learning/machine learning-based medical devices in Japan as of 2020: A systematic review
por: Aisu, Nao, et al.
Publicado: (2022)

2015 Review of Newly Approved Oncologic Therapies
por: Medina, Patrick, et al.
Publicado: (2016)

Does Industry‐Conducted All‐Case Surveillance of Newly Approved Oncology Drugs Contribute to the Revision of Package Inserts in Japan?
por: Suzuki, Akiyuki, et al.
Publicado: (2019)

Is Case Volume the Only Surrogate for Oncologic Surgical Quality?
por: Greene, Frederick L.
Publicado: (2007)

Lifecycle management of orphan drugs approved in Japan
por: Seki, Kiyoshi, et al.
Publicado: (2022)

Brain Tumor Registry of Japan (2001–2004)
Publicado: (2014)

Biosimilar agents in oncology/haematology: from approval to practice
por: Niederwieser, Dietger, et al.
Publicado: (2011)

Radiation Oncology Device Approval in the United States and Canada
por: Beers, Craig A, et al.
Publicado: (2019)

Trends in dental visits during the state of emergency for COVID-19 in Japan: a retrospective observational study
por: Takeda, Asuka, et al.
Publicado: (2022)

A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020
por: Teixeira, Maria Manuel, et al.
Publicado: (2022)

Association of Vaccine Confidence and Hesitancy in Three Phases of COVID-19 Vaccine Approval and Introduction in Japan
por: Tokiya, Mikiko, et al.
Publicado: (2022)

The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer
por: Tokunaga, Hideki, et al.
Publicado: (2021)

Efficacy comparison of duloxetine and SSRIs at doses approved in Japan
por: Harada, Eiji, et al.
Publicado: (2015)

Epidemiology of Diphyllobothrium nihonkaiense Diphyllobothriasis, Japan, 2001–2016
por: Ikuno, Hiroshi, et al.
Publicado: (2018)

Widening Socioeconomic Inequalities in Smoking in Japan, 2001–2016
por: Tanaka, Hirokazu, et al.
Publicado: (2021)

Clinical Trial Design and Drug Approval in Oncology: A Primer for the Advanced Practitioner in Oncology
por: Kurtin, Sandra E., et al.
Publicado: (2020)

Timing of Confirmatory Trials for Drugs Granted Accelerated Approval Based on Surrogate Measures From 2012 to 2021
por: Deshmukh, Anjali D., et al.
Publicado: (2023)

Trends in Canadian prescription drug purchasing: 2001–2020
por: Hofmeister, Mark, et al.
Publicado: (2022)

Efficacy End Points and Dose Analysis of Food and Drug Administration-Approved Novel Drugs in 2020
por: Tang, Albert
Publicado: (2022)

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
por: Miljković, Miloš D., et al.
Publicado: (2022)

Contemporary oncology trials, drug approvals and the physician-patient relationship
por: Schnog, John-John B., et al.
Publicado: (2022)

Single-arm trials for domestic oncology drug approvals in China
por: Zhang, Hong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bqlmgt353inb7e6hi4p3kgtg7j